Mochi Health Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)

Mochi Health is one of the larger weight-management telehealth companies that rose to prominence selling tirzepatide by subscription, and "is Mochi worth it?" is now one of the most-asked questions in the GLP-1 world. This review takes the honest, non-promotional angle: what Mochi actually is, what its tirzepatide costs in 2026, the all-important compounded-versus-brand distinction, and the specific things to check before you hand over a card number. We have no affiliation with Mochi; pricing and program details below are described as current-2026 information and change frequently, so treat every dollar figure as a starting point to verify on Mochi's own site, not a quote.

What Mochi Health is

Mochi Health is a direct-to-consumer telehealth platform: you complete an online intake, a licensed clinician reviews your history over video or asynchronous messaging, and — if you're a candidate — a prescription for a GLP-1/GIP medication (tirzepatide or semaglutide) is issued and shipped from a partner pharmacy. The model bundles the prescriber visit, ongoing dose management, and the medication into a recurring monthly membership. There is no brick-and-mortar clinic; the entire relationship is online. This is the same broad model used by Ro, Henry Meds, Sequence/Hims and many others — the differences are in price, which drug version they dispense, and the fine print.

The single most important question: compounded or brand?

Before any price comparison, you have to know which tirzepatide a program dispenses, because there are two very different products that share the name:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (for weight management and obstructive sleep apnea) and Mounjaro (for type 2 diabetes). This is the exact molecule, formulation and dose studied in the pivotal trials.
• •Compounded tirzepatide is made by a compounding pharmacy, is not FDA-approved, and is not the product tested in those trials.

This distinction is not academic in 2026. During the 2022–2024 tirzepatide shortage, compounding pharmacies were broadly permitted to make copies, and low-priced compounded tirzepatide was the entire value proposition for many telehealth subscriptions. That window has closed. The FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement-discretion period that had allowed routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities). Programs that still offer compounded tirzepatide today typically do so through narrower routes — personalization exceptions, or salt forms such as tirzepatide acetate — that remain legally and clinically contested. We walk through the full regulatory timeline in our guide to whether compounded tirzepatide is still legal in 2026. The practical takeaway for any Mochi review: confirm in writing whether you are being prescribed brand Zepbound/Mounjaro or a compounded version, because the price difference you see is almost entirely explained by that one fact.

What Mochi's tirzepatide costs in 2026

Mochi has historically marketed tirzepatide on a membership model — a monthly fee that, in many of its plans, bundles the clinician care with the medication, with the headline price stepping up as your dose increases over the titration schedule. Promotional first-month pricing has often been advertised well below the ongoing rate, which is the figure that actually matters for a long-term medication. Because the company has repeatedly restructured its pricing — and because what's included (medication vs. "membership only") varies by plan and by whether you're on a compounded or brand product — any single number we print here would be stale within weeks.

The honest way to read Mochi's pricing is to ask four questions and get the answers in writing before you pay:

1. 1.Is the medication included in the membership, or billed separately? A low membership fee with the drug billed on top is a very different total than an all-in price.
2. 2.Is the advertised price a first-month promo or the ongoing rate? Tirzepatide is taken for the long term; the renewal price is the real cost.
3. 3.Does the price change as my dose climbs? Higher-dose tiers frequently cost more.
4. 4.Compounded or brand? This determines whether you can fairly compare the price to Lilly's own self-pay channel.

That last point is the crucial benchmark. Eli Lilly's LillyDirect self-pay program sells brand Zepbound single-dose vials at roughly $299–$449 per month depending on dose (prices effective February 23, 2026; a 28-day supply). Any telehealth subscription dispensing brand tirzepatide should be measured against that floor. A subscription dispensing compounded tirzepatide may quote a lower number, but you are then comparing a non-FDA-approved product to an approved one — not a like-for-like deal. For the full cash-price landscape, see our breakdown of Zepbound cost and savings and where vials beat pens on self-pay.

How the care model holds up

On the clinical side, the telehealth membership model has genuine strengths: it lowers the friction of getting started, provides structured dose titration and messaging support, and for many people is the difference between starting an effective therapy and not. The legitimate concerns are the ones that apply to any subscription GLP-1 program: continuity of care (what happens if you need to pause for side effects, surgery, or pregnancy planning), how easy it is to cancel (subscription weight-loss services have drawn consumer complaints across the industry about hard-to-cancel billing), and whether the prescriber relationship is robust enough to manage the drug's real warnings. Tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning, among others — so the quality of medical oversight matters. Our companion guides on Zepbound side effects, tirzepatide and the gallbladder, and the thyroid cancer warning cover what good oversight should be watching for.

Does the drug itself work? (Separate from the provider)

It's worth separating the provider from the medication. Tirzepatide's efficacy is not in question: in the pivotal 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹. Head-to-head against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14% over 72 weeks². That trial-grade efficacy applies to brand tirzepatide (the molecule studied); compounded versions were never tested in those trials, which is the heart of the compounded-vs-brand caveat. For the complete benefit-and-risk picture, see our tirzepatide evidence guide.

The honest verdict

Mochi Health is a legitimate, established telehealth route to tirzepatide, and for people who want a low-friction, all-in-one program with built-in dose management, it can be a reasonable way to start. But three caveats decide whether it's the right choice for you. First, nail down whether you're getting brand or compounded tirzepatide — that single fact reframes every price comparison. Second, compare the ongoing (not promo) all-in monthly cost against the LillyDirect self-pay floor of ~$299–$449 for brand vials; if Mochi's brand price is far above that, you're paying a premium for convenience, and if its compounded price is far below, you're trading FDA approval for savings. Third, read the cancellation terms before you subscribe. For a side-by-side look at vetted ways to get the real, FDA-approved drug, see our best place to get Zepbound online roundup and our best tirzepatide providers overview.